: iStockAnalyst.com Symbols Feed

BioMed News Bytes: Dendreon, Chelsea, Cytori, Cephalon, OraSure, Genzyme, Lixte

Thu, 24 Sep 2009 23:01:08 GMT

On 4/28/09, Dendreon (NASDAQ: DNDN) announced that its experimental cancer vaccine Provenge extended the life of patients with advanced prostate cancer by a median of 4.1 months, which is one month longer than the only other treatment option, Taxotere.[More...]

Market Closing: Nasdaq Leads Decliners; Oil at 2-Month Low

Thu, 24 Sep 2009 20:25:00 GMT

Stocks end lower after disappointing housing data sapped early market strength. The tech-concentrated Nasdaq closes down 1%, as does the S&P 500. The DJIA ends with a slimmer 0.5% decline. Oil hit a two-month low at $65.89 a barrel, also dragging on stocks.[More...]

FDA Calendar Updates: AZN, BMY, OSUR, CPD, INSM,

Thu, 25 Jun 2009 20:26:37 GMT

Below is a summary of updates to the BioMedReports.com FDA Calendar, which includes a database of over 200 entries. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com, the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response lette (...)[More...]

CombiMatrix: Array Of Sunshine In '09?

Thu, 15 Jan 2009 14:08:00 GMT

The accompanying table (click to enlarge) includes statistics for all 40 companies included in the ETF Innovators Emerging Diagnostics Index of stocks with market caps of less than $150M and an average market value of $50M. The index has lost nearly 54% of its value in the past year, compared to declines of about 40% each for the S&P 500 SPDR ETF (SPY) + iShares Russell Micro-Cap ETF (IWC), 29% for the Healthcare Sector SPDR (XLV), and 15% for the SPDR S&P Biotech ETF (XBI).[More...]

In Search of Healthcare Diamonds In The Rough

Mon, 12 Jan 2009 04:52:00 GMT

While we are not even halfway through January, the healthcare sector is already active with deal-making, ranging from the rumored $95 buyout of biotech giant Genetech (DNA) by Roche (RHHBY) to Endo's (ENDP) purchase of small-cap, specialty pharma Indevus (IDEV) to Sequenom's (SQNM) $41M offer for emerging diagnostic company EXACT Sciences (EXAS) – which was promptly rebuffed by EXACT's board after the market close on Monday on the promise of a better deal in the works for shareholders. Larger bio-pharma and diagnostic companies are opportunistically looking to expand their product offerings, pipeline prospects, patent portfolios, and drug discovery technology platforms given the huge declines in the stock prices of small/micro-cap stocks in the healthcare sector. With that in mind, I sorted through the ETF Innovators indexes for a list of a dozen[More...]

A New Emerging Diagnostics Index

Fri, 26 Dec 2008 15:27:00 GMT

The accompanying table (click to enlarge) includes 39 companies in the ETF Innovators (ETFI) Emerging Diagnostics Index of U.S.-listed stocks with market caps of $10-$200M. The index includes diabetes care device makers such as DexCom (DXCM), personalized medicine lab service providers such as Clarient (CLRT), clinical diagnostic test developers such as OraSure (OSUR), diagnostic imaging service providers such as Virtual Radiologic (VRAD), diagnostic equipment makers such as Vision Sciences (VSCI), and genetic[More...]

Hump Day Catalysts

Wed, 07 May 2008 15:39:51 GMT

Good morning. Premarket futures are pointing to a flat start as investors look for any reason (or no reason) to move the market higher.[More...]

Orasure sees profit on higher sales: But the Bethlehem maker of HIV tests, other products, expects to end year in the red.

Thu, 05 Nov 2009 22:49:00 GMT

Nov. 5--Orasure Technologies, the Bethlehem maker of tests for HIV and other medical products, reported its first quarterly profit this year due to strong sales growth.
The company on Wednesday reported third-quarter earnings of $1.8 million, or 4 cents per share, which compares with a loss of $1.8 million, or 4 cents per share in the same period a year ago.
Sales of the company's leading product, the OraQuick HIV test, were down in the second quarter due to the manufacturing problems.

: iStockAnalyst.com Symbols Feed

BioMed News Bytes: Dendreon, Chelsea, Cytori, Cephalon, OraSure, Genzyme, Lixte

Market Closing: Nasdaq Leads Decliners; Oil at 2-Month Low

FDA Calendar Updates: AZN, BMY, OSUR, CPD, INSM,

CombiMatrix: Array Of Sunshine In '09?

In Search of Healthcare Diamonds In The Rough

A New Emerging Diagnostics Index

Hump Day Catalysts

Orasure sees profit on higher sales: But the Bethlehem maker of HIV tests, other products, expects to end year in the red.

Lehigh Valley Business Owners Say Electric Rate Hikes Will Put Pennsylvanians Out of Work: Large Power Users Urge Lawmakers to Curb Looming Price Spike

OraSure Technologies Announces 2010 Annual Meeting Date

OraSure Announces 2009 Second Quarter Financial Results and Resumption of Full-Scale OraQuick(R) Production

OraSure Technologies Earnings Conference Call Invitation

OraSure Technologies, Inc. (OSUR) Chief Executive Officer to Ring the NASDAQ Stock Market Opening Bell

OraSure Technologies Provides Update on Clinical Development Programs and OraQuick Manufacturing

OraSure Announces 2009 First Quarter Financial Results

OraSure Technologies to Webcast Annual Meeting of Stockholders

OraSure Announces Fourth Quarter and Full Year 2008 Financial Results

OraSure Technologies Earnings Conference Call Invitation - Feb 4 2009 6:15AM

U.S. FDA Approves OraQuick ADVANCE(R) 12-Month Shelf Life Dating

Form 4 FORMICA P MICHAEL For: Aug 19 (10K)

Form 4 Michels Douglas A For: Mar 31 (10K)

Form 4 LANCASTER RONNY B For: Sep 29 (10K)

Form 4 SPAIR RONALD H For: Sep 29 (10K)

Form 4 Michels Douglas A For: Sep 30 (10K)

Form 4 Lee Stephen R For: Sep 29 (10K)

Form 4 KUNA MARK L For: Sep 29 (10K)

Form 4 ORASURE TECHNOLOGIES For: Sep 23 Filed by: Lee Stephen R (10K)

Form 4 ORASURE TECHNOLOGIES For: Aug 19 Filed by: FORMICA P MICHAEL (10K)

Form 4 ORASURE TECHNOLOGIES For: Aug 14 Filed by: SPAIR RONALD H (10K)